Quantcast

Latest Genzyme Stories

2014-04-29 04:21:53

PARIS, April 29, 2014 /PRNewswire/ -- Sanofi, a global and diversified healthcare leader, reports results for the first-quarter of 2014. Jerome Contamine, Chief Financial Officer of Sanofi, comments on results and R&D pipeline. Watch video interview and read transcript: http://www.eurobusinessmedia.com/ceo-direct/sanofi/interview-with-cfo-jerome-contamine-q1-2014-results,2014-04-28,1175?utm_source=ceo-direct&utm_medium=wire Topics covered in the...

2014-04-15 12:30:41

Market Access Challenges for Sanofi/Genzyme's Aubagio Highlight the Hurdles New Multiple Sclerosis Agents Face in Europe, According to Findings from Decision Resources Group BURLINGTON, Mass., April 15, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed neurologists in France, Germany, Italy, Spain, and the United Kingdom (EU5) project that 16 percent of their diagnosed relapsing-remitting multiple sclerosis (MS) patients on average will receive Biogen Idec's Tecfidera within...

2014-03-18 08:29:03

For MS Awareness Month, MSAA Launches Effort to Get More People with MS in the Pool CHERRY HILL, N.J., March 18, 2014 /PRNewswire/ -- In honor of Multiple Sclerosis (MS) Awareness Month, the Multiple Sclerosis Association of America (MSAA), through a collaborative partnership with Genzyme, a Sanofi company, is proud to announce the stories from three individuals in the MS community who describe how swimming has helped manage their MS symptoms and improve their overall well-being. Today, MSAA...

2014-03-05 12:27:25

Minerva president Rogerio Vivaldi and board chairman Marc Beer leading strategy to advance pipeline of novel therapies targeting applications in neuropsychiatry. CAMBRIDGE, Mass., March 5, 2014 /PRNewswire/ -- Minerva Neurosciences, Inc., a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced the launch of the new company web site (www.minervaneurosciences.com) following the successful transfer of the Minerva Neurosciences corporate...

2014-02-27 16:25:58

TORONTO, Feb. 27, 2014 /CNW/ - The following B-Roll is available by Video On-Demand web download: STORY SUMMARY: Genzyme, a Sanofi company, today announced the Canadian availability of (Pr)LEMTRADA(TM)(alemtuzumab) for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS), with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies. LEMTRADA 12 mg has a...

2014-02-27 08:29:40

MISSISSAUGA, ON, Feb. 27, 2014 /CNW/ - Genzyme, a Sanofi company, today announced the Canadian availability of (Pr)LEMTRADA(TM) (alemtuzumab) for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS), with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies. LEMTRADA 12 mg has a dosing and administration schedule of two annual treatment courses. The first...

2014-02-27 08:26:12

TORONTO, Feb. 27, 2014 /CNW/ - The following B-Roll is available by Video On-Demand web download: STORY SUMMARY: Genzyme, a Sanofi company, today announced the Canadian availability of (Pr)LEMTRADA(TM)(alemtuzumab) for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS), with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies. LEMTRADA 12 mg has a...

2014-02-12 12:31:06

LONDON, Feb. 12, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Translational Regenerative Medicine: Market Prospects 2014-2024Report DetailsOur new study shows you the commercial potential of regenerative treatmentsWhat does the future hold for regenerative medicine? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.Our study lets you assess regenerative medicine: cell-based...

2014-02-06 08:27:40

PARIS, Feb. 6, 2014 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q4 2013 Change (reported) Change (CER) 2013 Change (reported) Change (CER) Net sales EUR8,457m -0.8% +6.5% EUR32,951m -5.7% -0.5% Business net income(1) EUR1,810m...

2014-02-05 08:29:22

Strategic Business Leader Brings Complementary Product Commercialization and Rare Disease Expertise SAN DIEGO, Feb. 5, 2014 /PRNewswire/ -- aTyr Pharma ("aTyr"), an innovative biotherapeutics enterprise, announced today that Frederic Chereau has joined aTyr as president and chief operating officer. Mr. Chereau has more than 20 years of experience in bringing new rare disease products to market and has held key leadership positions at Shire and Genzyme. Mr. Chereau's appointment will...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.